Kieburtz, Karl, Landwehrmeyer, G. B., HORIZON Investigators of the Huntington Study Group,, European Huntington's Disease Network,

BACKGROUND Latrepirdine is an orally administered experimental small molecule that was initially developed as an antihistamine and subsequently was shown to stabilize mitochondrial membranes and function, which might be impaired in Huntington disease. OBJECTIVE To determine the effect of latrepirdine on cognition and global function in patients with mild to moderate Huntington disease. DESIGN Randomized, […]

Kieburtz, Karl, McDermott, Michael P., Voss, Tiffini S., Corey-Bloom, Jody, Deuel, Lisa M., Dorsey, E. Ray, Factor, Stewart, Geschwind, Michael D., Hodgeman, Karen, Kayson, Elise, Noonberg, Sarah, Pourfar, Michael, Rabinowitz, Karen, Ravina, Bernard, Sanchez-Ramos, Juan, Seely, Lynn, Walker, Francis, Feigin, Andrew

Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]

Cruz, Joana, Marques, Alda, Barbosa, Ana L., Figueiredo, Daniela, Sousa, Liliana

Involving institutionalized people with dementia in their routines may be challenging, particularly in advanced stages of the disease. Motor and multisensory stimulation may help to maintain or improve residents’ remaining abilities such as communication and self-care. This study examines the effects of a motor and multisensory-based approach on the behavior of 6 residents with moderate-to-severe […]

Galasko, D., Bell, J., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C., Thomas, R. G., Aisen, P. S.

Objective: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).; Methods: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State Examination score 14-26 were randomized to PF-04494700 60 mg/day × 6 days, […]